Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A.
Diamantstein
T
T
Institut für Immunologie, Klinikum Steglitz, Freie Universität, Berlin, F.R.G.
Mouzaki
A
A
Osawa
H
H
Volk
H D
HD
Hahn
H J
HJ
Kirkman
R L
RL
Strom
T B
TB
Tilney
N L
NL
Kupiec-Weglinski
J W
JW
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003524:Cyclosporins / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004357:Drug Synergism; D006084:Graft Rejection; D006087:Graft vs Host Reaction; D007167:Immunotherapy; D007376:Interleukin-2 / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D007376:Interleukin-2; D015375:Receptors, Interleukin-2